Index RUT
P/E 13.44
EPS (ttm) 2.40
Insider Own 2.46%
Shs Outstand 31.87M
Perf Week -5.78%
Market Cap 1.06B
Forward P/E 4.72
EPS next Y 6.84
Insider Trans -24.73%
Shs Float 31.82M
Perf Month -13.97%
Income 93.29M
PEG 24.44
EPS next Q 1.46
Inst Own 122.52%
Short Float 21.79%
Perf Quarter -12.85%
Sales 566.92M
P/S 1.86
EPS this Y 13.77%
Inst Trans -1.89%
Short Ratio 15.12
Perf Half Y 25.91%
Book/sh 6.79
P/B 4.75
EPS next Y 9.96%
ROA 8.01%
Short Interest 6.93M
Perf Year 44.38%
Cash/sh 9.72
P/C 3.32
EPS next 5Y 0.55%
ROE 46.43%
52W Range 20.83 - 40.95
Perf YTD 4.84%
Dividend Est. -
P/FCF 3.43
EPS past 5Y -
ROI 13.97%
52W High -21.20%
Beta 0.96
Dividend TTM -
Quick Ratio 1.14
Sales past 5Y 17.87%
Gross Margin 60.01%
52W Low 54.92%
ATR (14) 1.34
Dividend Ex-Date -
Current Ratio 1.21
EPS Y/Y TTM 428.92%
Oper. Margin 33.83%
RSI (14) 38.97
Volatility 3.80% 3.91%
Employees 197
Debt/Eq 2.84
Sales Y/Y TTM 8.00%
Profit Margin 16.46%
Recom 2.20
Target Price 40.00
Option/Short Yes / Yes
LT Debt/Eq 2.01
EPS Q/Q 239.41%
Payout 0.00%
Rel Volume 1.13
Prev Close 33.14
Sales Surprise -1.37%
EPS Surprise -1.38%
Sales Q/Q 0.11%
Earnings May 09 AMC
Avg Volume 458.64K
Price 32.27
SMA20 -6.31%
SMA50 -11.12%
SMA200 7.00%
Trades
Volume 516,142
Change -2.63%
Date
Action
Analyst
Rating Change
Price Target Change
May-10-24 Downgrade
Piper Sandler
Overweight → Neutral
$39
May-10-24 Downgrade
Needham
Buy → Hold
Jan-04-24 Downgrade
Jefferies
Buy → Hold
$30 → $37
Aug-25-23 Reiterated
Needham
Buy
$35 → $36
May-02-23 Resumed
Jefferies
Buy
$30
Aug-08-22 Downgrade
H.C. Wainwright
Buy → Neutral
Feb-15-22 Upgrade
Cantor Fitzgerald
Neutral → Overweight
$18 → $26
Aug-06-21 Downgrade
Cantor Fitzgerald
Overweight → Neutral
Jan-11-21 Reiterated
H.C. Wainwright
Buy
$29 → $33
Jul-14-20 Initiated
BWS Financial
Sell
$8
May-27-20 Initiated
Guggenheim
Neutral
Feb-19-20 Resumed
Jefferies
Buy
$43
Oct-30-19 Reiterated
Needham
Buy
$33 → $25
May-03-19 Resumed
H.C. Wainwright
Buy
$23
Apr-12-19 Resumed
Janney
Buy
$29
Mar-20-19 Initiated
SunTrust
Hold
$22
Jan-16-19 Reiterated
Needham
Buy
$35 → $33
Mar-08-18 Reiterated
H.C. Wainwright
Buy
$21 → $33
Feb-07-18 Reiterated
Needham
Buy
$28 → $35
Dec-05-17 Reiterated
Needham
Buy
$25 → $28
Show Previous Ratings
May-30-24 02:40AM
May-29-24 08:00AM
May-13-24 09:31AM
08:00AM
May-10-24 02:01PM
12:17PM
Loading…
12:17PM
(Associated Press Finance)
09:51AM
04:48AM
May-09-24 06:00PM
05:40PM
04:36PM
(Associated Press Finance)
04:02PM
04:01PM
May-07-24 09:15AM
May-02-24 10:01AM
09:45AM
Loading…
Apr-29-24 09:45AM
08:00AM
Apr-25-24 08:00AM
Apr-11-24 08:00AM
Apr-09-24 06:00PM
Apr-03-24 08:00AM
Mar-18-24 09:40AM
Mar-13-24 12:45PM
Mar-04-24 08:28PM
Mar-01-24 12:00PM
Feb-29-24 09:40AM
Feb-28-24 11:25PM
Feb-27-24 10:41AM
(Investor's Business Daily)
Feb-23-24 10:20AM
06:09AM
(Thomson Reuters StreetEvents)
07:00PM
Loading…
Feb-22-24 07:00PM
05:06PM
(Associated Press Finance)
04:43PM
04:09PM
04:00AM
Feb-08-24 08:00AM
Jan-31-24 08:03AM
Jan-24-24 12:10PM
Jan-18-24 07:58PM
Jan-09-24 08:34AM
Jan-04-24 10:40AM
03:17AM
Jan-03-24 08:00AM
Dec-23-23 01:01AM
Dec-21-23 05:01PM
Nov-30-23 07:04AM
Nov-27-23 08:00AM
Nov-14-23 03:08PM
Nov-09-23 08:00AM
Nov-08-23 09:53AM
09:30AM
08:00AM
Nov-07-23 04:44PM
(Associated Press Finance)
04:01PM
Nov-01-23 10:01AM
Oct-31-23 10:01AM
Oct-24-23 08:00AM
Oct-12-23 03:47AM
Oct-06-23 09:40AM
Aug-28-23 08:00AM
Aug-24-23 08:00AM
Aug-07-23 07:30AM
Aug-03-23 08:30PM
05:35PM
04:29PM
(Associated Press Finance)
04:01PM
Jul-28-23 02:56PM
Jul-20-23 08:00AM
Jul-07-23 08:52AM
Jun-22-23 08:30AM
Jun-21-23 08:00PM
Jun-01-23 08:00AM
May-18-23 01:50PM
May-09-23 03:15PM
May-04-23 06:30PM
05:55PM
04:47PM
04:01PM
May-03-23 09:15AM
Apr-27-23 10:03AM
Apr-26-23 08:00PM
Apr-20-23 08:00AM
Apr-11-23 08:00AM
Mar-01-23 11:40AM
07:54AM
Feb-26-23 07:02AM
Feb-24-23 08:52AM
(Thomson Reuters StreetEvents)
Feb-23-23 05:25PM
04:01PM
Feb-22-23 09:06AM
08:00AM
Feb-21-23 10:00AM
Feb-16-23 10:01AM
Feb-13-23 11:40AM
Feb-07-23 09:54PM
Feb-06-23 04:08PM
04:07PM
Jan-31-23 05:00AM
Jan-30-23 06:35AM
Jan-28-23 07:41AM
Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Tupper Colleen EVP & Chief Financial Officer May 28 '24 Sale 34.21 19,710 674,368 130,845 May 29 04:29 PM Dreyer Scott EVP & Chief Commercial Officer May 24 '24 Option Exercise 24.03 23,791 571,698 162,709 May 28 04:22 PM Dreyer Scott EVP & Chief Commercial Officer May 24 '24 Sale 33.98 56,807 1,930,455 105,902 May 28 04:22 PM Dreyer Scott EVP & Chief Commercial Officer May 23 '24 Option Exercise 24.03 51,209 1,230,552 190,127 May 28 04:22 PM Dreyer Scott EVP & Chief Commercial Officer May 23 '24 Sale 33.82 51,209 1,732,093 138,918 May 28 04:22 PM BOHLIN GAREN G Director May 14 '24 Option Exercise 5.73 28,985 166,084 73,760 May 16 07:20 PM BOHLIN GAREN G Director May 14 '24 Sale 32.30 28,985 936,311 44,775 May 16 07:20 PM Smith Thomas B EVP and Chief Medical Officer Feb 29 '24 Sale 36.76 995 36,580 63,409 Mar 04 04:26 PM Dreyer Scott EVP & Chief Commercial Officer Feb 26 '24 Sale 36.43 10,000 364,270 138,918 Feb 28 04:14 PM Dreyer Scott EVP & Chief Commercial Officer Jan 16 '24 Sale 32.28 23,560 760,519 111,322 Jan 18 04:19 PM Ciaffoni Joseph President and CEO Dec 21 '23 Option Exercise 21.34 4,357 92,978 279,357 Dec 22 04:36 PM Ciaffoni Joseph President and CEO Dec 21 '23 Sale 30.38 4,357 132,377 275,000 Dec 22 04:36 PM Ciaffoni Joseph President and CEO Dec 20 '23 Option Exercise 21.34 26,454 564,528 301,454 Dec 20 05:51 PM Ciaffoni Joseph President and CEO Dec 20 '23 Sale 30.40 26,454 804,210 275,000 Dec 20 05:51 PM Ciaffoni Joseph President and CEO Dec 19 '23 Option Exercise 21.34 14,516 309,771 289,516 Dec 20 05:51 PM Ciaffoni Joseph President and CEO Dec 19 '23 Sale 30.03 14,516 435,942 275,000 Dec 20 05:51 PM Ciaffoni Joseph President and CEO Dec 18 '23 Option Exercise 21.34 27,798 593,209 302,798 Dec 20 05:51 PM Ciaffoni Joseph President and CEO Dec 18 '23 Sale 30.04 27,798 834,935 275,000 Dec 20 05:51 PM Kuhlmann Shirley R. EVP and General Counsel Nov 27 '23 Option Exercise 15.90 25,600 407,040 145,118 Nov 29 04:32 PM Kuhlmann Shirley R. EVP and General Counsel Nov 27 '23 Sale 25.78 25,600 660,014 119,518 Nov 29 04:32 PM Kuhlmann Shirley R. EVP and General Counsel Jun 26 '23 Sale 21.72 17,984 390,633 119,518 Jun 28 04:08 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite